Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons

被引:69
作者
Gmeiner, William H. [1 ]
Reinhold, William C. [2 ]
Pommier, Yves [2 ]
机构
[1] Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA
[2] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
THYMIDYLATE SYNTHASE INHIBITION; ANTICANCER DRUG SCREEN; EXPRESSION PROFILES; BREAST-CANCER; PANEL; SENSITIVITY; GENES; 5-FLUOROURACIL; BIOSYNTHESIS; DETERMINANTS;
D O I
10.1158/1535-7163.MCT-10-0674
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A profile of microRNA (miRNA) and mRNA expression patterns across the NCI-60 cell-line screen was analyzed to identify expression signatures that correlate with sensitivity to FdUMP[10], fluorouracil (5FU), floxuridine (FdU), topotecan, and irinotecan. Genome-wide profile analyses revealed FdUMP[10] resembles FdU most closely and shows dissimilarities with 5FU. FdUMP[10] had the largest dynamic range of any of these drugs across the NCI-60 indicative of cancer cell-specific activity. Genes involved in endocytosis, such as clathrin (CLTC), SNF8, annexin A6 (ANXA6), and amyloid protein-binding 2 (APPBP2) uniquely correlated with sensitivity to FdUMP[10], consistent with a protein-mediated cellular uptake of FdUMP[10]. Genes involved in nucleotide metabolism were enriched for the three fluoropyrimidine drugs, with the expression profile for 5FU correlated to an RNA-mediated cytotoxic mechanism, whereas expression of glycosyltransferases (XYLT2) that use UDP sugars as substrates and the nucleoside diphosphatase and metastasis suppressor NM23 (NME1) were associated with FdUMP[10] sensitivity. Topotecan and irinotecan had significant negative correlations with miR-24, a miRNA with a high aggregate P(CT) score for topoisomerase 1 (Top1). Our results reveal significant new correlations between FdUMP[10] and Top1 poisons, as well as new information on the unique cytotoxic mechanism and genomic signature of FdUMP[10]. Mol Cancer Ther; 9(12); 3105-14. (C) 2010 AACR.
引用
收藏
页码:3105 / 3114
页数:10
相关论文
共 39 条
[1]  
Bijnsdorp IV, 2007, ONCOL REP, V18, P287
[2]   Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic? [J].
Bonnefoi, Herve ;
Underhill, Craig ;
Iggo, Richard ;
Cameron, David .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1733-1743
[3]   SOME PRACTICAL CONSIDERATIONS AND APPLICATIONS OF THE NATIONAL-CANCER-INSTITUTE IN-VITRO ANTICANCER DRUG DISCOVERY SCREEN [J].
BOYD, MR ;
PAULI, KD .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) :91-109
[4]   Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence [J].
Brody, Jonathan R. ;
Hucl, Tomas ;
Costantino, Christina L. ;
Eshleman, James R. ;
Gallmeier, Eike ;
Zhu, Heng ;
van der Heijden, Michiel S. ;
Winter, Jordan M. ;
Wikiewicz, Agnieszka K. ;
Yeo, Charles J. ;
Kern, Scott E. .
CANCER RESEARCH, 2009, 69 (03) :984-991
[5]   Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme of glycosaminoglycan biosynthesis [J].
Condac, Eduard ;
Silasi-Mansat, Robert ;
Kosanke, Stanley ;
Schoeb, Trenton ;
Towner, Rheal ;
Lupu, Florea ;
Cummings, Richard D. ;
Hinsdale, Myron E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (22) :9416-9421
[6]   Nme protein family evolutionary history, a vertebrate perspective [J].
Desvignes, Thomas ;
Pontarotti, Pierre ;
Fauvel, Christian ;
Bobe, Julien .
BMC EVOLUTIONARY BIOLOGY, 2009, 9
[7]   Enhanced DNA-directed effects of FdUMP[10] compared to 5FU [J].
Gmeiner, WH ;
Trump, E ;
Wei, C .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (1-2) :401-410
[8]   Novel chemical strategies for thymidylate synthase inhibition [J].
Gmeiner, WH .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (02) :191-202
[9]   Genetic determinants for activated fluoropyrimidine chemotherapy [J].
Gmeiner, William H. .
DRUG DEVELOPMENT RESEARCH, 2006, 67 (02) :119-129
[10]  
GOLDWASSER F, 1995, CANCER RES, V55, P2116